Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Serum hepcidin a biomarker for restless leg syndrome

30 Jul 2020

Regardless of treatment, serum hepcidin is elevated in patients with restless leg syndrome (RLS) and may act as a biomarker for this condition, a recent study has found.

The study included 102 drug-free RLS patients (median age, 58.9 years; 63 women) whose serum levels of hepcidin and ferritin were measured using the appropriate immunoassays. Participants also underwent a one-night polysomnography in the sleep laboratory. A parallel group of 73 controls (median age, 56.8 years; 45 women) was also included.

Hepcidin levels were significantly elevated in RLS patients even after controlling for body mass index (median, 18.36 vs 11.89 µg/L; p<0.01). Categorizing patients into tertiles of hepcidin showed that that number of patients in each category grew with increasing hepcidin concentration. No such trend was observed for controls.

Receiver operating characteristic curve analysis found that at a hepcidin cut-off of 18.1 µg/L, serum concentrations became a decent discriminator of RLS, with a sensitivity of 52 percent and a specificity of 75 percent.

In contrast, ferritin was slightly higher in RLS patients than in controls upon unadjusted analysis, and this interaction was attenuated after controlling for body mass index.

“Due to the easy-to-use [enzyme-linked immunosorbent assay], hepcidin quantification could be implemented in the routine clinical practice, in view of a possible personalized approach before therapeutic management and potentially with hepcidin antagonists in some patients with RLS,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.